• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Brand-Specific Enhanced Safety Surveillance Study of GSK ’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season
ConclusionThis ESS study assessed AEs in near real time. The COVID-19 pandemic did not alter the safety profile of GSK ’s IIV4. No safety signals were detected during the study, which confirms the excellent safety profile of GSK’s IIV4.
Source: Infectious Diseases and Therapy - December 27, 2021 Category: Infectious Diseases Source Type: research

Brand-Specific Enhanced Safety Surveillance of GSK ’s Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season
ConclusionIn compliance with EMA guidance, this study design allowed for near real-time assessment of AEs. No safety signals were detected at any point during the study period. The study supports and confirms the acceptable safety profile of GSK ’s IIV4.ClinicalTrials.gov identifierNCT03688620.
Source: Drug Safety - December 27, 2019 Category: Drugs & Pharmacology Source Type: research

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
CONCLUSION: The IIV4 and PPV23 can be co-administered without reducing antibody responses reflecting protection against influenza or pneumococcal disease. Co-administration of PPV23 at the annual influenza vaccination visit may improve uptake. Comorbidities had no impact on IIV4 immunogenicity, supporting its value in older adults with chronic medical conditions. Clinical Trial Registry Number: NCT02218697. PMID: 28987445 [PubMed - as supplied by publisher]
Source: Vaccine - October 5, 2017 Category: Allergy & Immunology Authors: Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL Tags: Vaccine Source Type: research

Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium
Conclusions: SP was responsible for approximately 5 % of SLRTIs observed in primary care in Belgium. Pneumococcal infection was associated with a significant increase in morbidity. Sixty-eight percent of serotypes causing SLRTI were potentially preventable by PCV13.
Source: BMC Family Practice - May 27, 2015 Category: Primary Care Authors: Johan FlamaingWilfried De BackerYves Van LaethemStéphane HeijmansAnnick Mignon Source Type: research